Oclacitinib
chemical compound
Oclacitinib, sold under the brand name Apoquel among others, is a veterinary medication used in the control of atopic dermatitis and pruritus from allergic dermatitis in dogs at least 12 months of age. Chemically, it is a synthetic cyclohexylamino-pyrrolopyrimidine Janus kinase inhibitor (JAK inhibitor) that is relatively selective for JAK1. It inhibits signal transduction when the JAK is activated and thereby helps downregulate expression of inflammatory cytokine.
Oclacitinib was approved for use in the United States in 2013 and in the European Union in 2023. A flavored chewable form was approved for use in the United States in 2023.
Uses
Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis. It is considered to be highly effective in dogs and has been established as safe for at least short-term use. Its efficacy is comparable to prednisolone early in treatment, and although oclacitinib has been shown to be more effective in the short term for itchiness and dermatitis, its long-term safety is incompletely established. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine.
“Oclacitinib” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Oclacitinib, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Oclacitinib” is worth following because a concise public description often conceals a longer documentary argument. Here, Oclacitinib, chemical and compound provides the most credible route into that argument.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 22, 2026. The linked authority identifier is Q27272209. 1 of 1 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 2013 and 2023.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Oclacitinib”, its source revision and the description used here.
- Expand the search: follow Oclacitinib primary sources, Oclacitinib archive and Oclacitinib research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Oclacitinib”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Oclacitinib” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.